Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mira Fitzek, Bianca Raffaelli & Uwe Reuter. (2022) Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraine. Expert Opinion on Pharmacotherapy 23:10, pages 1143-1153.
Read now
Read now
Enrique Martínez-Pías, David García-Azorín, Ane Minguez-Olaondo, Javier Trigo, Álvaro Sierra, Marina Ruiz & Ángel L. Guerrero. (2021) Triptanophobia in migraine: A case-control study on the causes and consequences of the nonuse of triptans in chronic migraine patients. Expert Review of Neurotherapeutics 21:1, pages 123-130.
Read now
Read now
László Vécsei, Délia Szok, Aliz Nyári & János Tajti. (2018) Treating status migrainosus in the emergency setting: what is the best strategy?. Expert Opinion on Pharmacotherapy 19:14, pages 1523-1531.
Read now
Read now
Abimael González-Hernández, Bruno A. Marichal-Cancino, Antoinette MaassenVanDenBrink & Carlos M. Villalón. (2018) Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opinion on Drug Metabolism & Toxicology 14:1, pages 25-41.
Read now
Read now
Matilde Capi, Fernando de Andrés, Luana Lionetto, Giovanna Gentile, Fabiola Cipolla, Andrea Negro, Marina Borro, Paolo Martelletti & Martina Curto. (2017) Lasmiditan for the treatment of migraine. Expert Opinion on Investigational Drugs 26:2, pages 227-234.
Read now
Read now
Articles from other publishers (24)
Lei Zhang, Diego Novick, Shiying Zhong, Jinnan Li, Chloe Walker, Lewis Harrison, James Jackson, Sophie Barlow & Sarah Cotton. (2023) Real-World Analysis of Clinical Characteristics, Treatment Patterns, and Patient-Reported Outcomes of Insufficient Responders and Responders to Prescribed Acute Migraine Treatment in China. Pain and Therapy 12:3, pages 751-769.
Crossref
Crossref
Mahsa Bagherzadeh-Fard, Mohammad Amin Yazdanifar, Mona Sadeghalvad & Nima Rezaei. (2023) Erenumab efficacy in migraine headache prophylaxis: A systematic review. International Immunopharmacology 117, pages 109366.
Crossref
Crossref
David Garcia-Azorin, Javier Díaz de Terán, Vicente González-Quintanilla, Ana Beatriz Gago-Veiga, Alicia González-Martínez, Ana Echavarría-Íñiguez & Ángel Luis Guerrero Peral. 2023. Headache Disorders in Pandemic Conditions. Headache Disorders in Pandemic Conditions
153
164
.
Robert P. Cowan, Michael J. Marmura, Hans-Christoph Diener, Amaal J. Starling, Jack Schim, Joe Hirman, Thomas Brevig & Roger Cady. (2022) Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study. The Journal of Headache and Pain 23:1.
Crossref
Crossref
János Tajti, Délia Szok, Aliz Nyári & László Vécsei. (2022) CGRP and CGRP-Receptor as Targets of Migraine Therapy: Brain
Prize-2021. CNS & Neurological Disorders - Drug Targets 21:6, pages 460-478.
Crossref
Crossref
Christopher Gottschalk, Anirban Basu, Andrew Blumenfeld, Bradley Torphy, Michael J Marmura, Jelena M Pavlovic, Paula K Dumas, Nim Lalvani & Dawn C Buse. (2022) The importance of an early onset of migraine preventive disease control: A roundtable discussion. Cephalalgia Reports 5, pages 251581632211345.
Crossref
Crossref
Eduardo Rivera-Mancilla & Antoinette MaassenVanDenBrink. 2022. Novel Synthetic Drugs in Migraine. Novel Synthetic Drugs in Migraine
1
17
.
Jessica Ailani, Rebecca C. Burch & Matthew S. Robbins. (2021) The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache: The Journal of Head and Face Pain 61:7, pages 1021-1039.
Crossref
Crossref
Kayla Rena Joyner & Kelsey Woods Morgan. (2020) Novel Therapies in Acute Migraine Management: Small-Molecule Calcitonin Gene-Receptor Antagonists and Serotonin 1F Receptor Agonist. Annals of Pharmacotherapy 55:6, pages 745-759.
Crossref
Crossref
Andrew M. Blumenfeld, Peter J. Goadsby, David W. Dodick, Susan Hutchinson, Chengcheng Liu, Michelle Finnegan, Joel M. Trugman & Armin Szegedi. (2021) Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis. Headache: The Journal of Head and Face Pain 61:3, pages 422-429.
Crossref
Crossref
Theresa Mallick-Searle & Maureen Moriarty. (2021) Unmet needs in the acute treatment of migraine attacks and the emerging role of calcitonin gene–related peptide receptor antagonists: An integrative review. Journal of the American Association of Nurse Practitioners 33:6, pages 419-428.
Crossref
Crossref
Heather Law, Andrew Avins, Robert Stahl, Michelle Goodreau, Alice Jacobson, Sylvia Sudat & Alice Pressman. (2020) Recruitment, retention, and adherence in a randomized feasibility trial of mindfulness-based stress reduction for patients with migraine. Complementary Therapies in Medicine 55, pages 102610.
Crossref
Crossref
Antonio Santoro, Massimiliano Copetti, Anna M. Miscio, Maurizio A. Leone & Andrea Fontana. (2020) Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy. Neurological Sciences 41:7, pages 1809-1820.
Crossref
Crossref
Swapnil Raut, Upasna Singh, Deepaneeta Sarmah, Aishika Datta, Falguni Baidya, Birva Shah, Mariya Bohra, Priya Jagtap, Ankan Sarkar, Kiran Kalia, Anupom Borah, Kunjan R. Dave, Dileep R. Yavagal & Pallab Bhattacharya. (2020) Migraine and Ischemic Stroke: Deciphering the Bidirectional Pathway. ACS Chemical Neuroscience 11:11, pages 1525-1538.
Crossref
Crossref
Jessica Ailani, Richard B. Lipton, Susan Hutchinson, Kerry Knievel, Kaifeng Lu, Matthew Butler, Sung Yun Yu, Michelle Finnegan, Lawrence Severt & Joel M. Trugman. (2020) Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial. Headache: The Journal of Head and Face Pain 60:1, pages 141-152.
Crossref
Crossref
László Vécsei, Melinda Lukács, János Tajti, Ferenc Fülöp, József Toldi & Lars Edvinsson. (2019) The Therapeutic Impact of New Migraine Discoveries. Current Medicinal Chemistry 26:34, pages 6261-6281.
Crossref
Crossref
Richard B. Lipton, Susan Hutchinson, Jessica Ailani, Michael L. Reed, Kristina M. Fanning, Aubrey Manack Adams & Dawn C. Buse. (2019) Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache: The Journal of Head and Face Pain 59:10, pages 1762-1772.
Crossref
Crossref
Jan Lewis Brandes, Suzanne Klise, John H Krege, Michael Case, Rashna Khanna, Raghavendra Vasudeva, Joel Raskin, Eric M Pearlman & David Kudrow. (2019) Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia 39:11, pages 1343-1357.
Crossref
Crossref
Kelemen Hajnal, Filep Bíborka-Erzsébet & Papp Lajos Attila. (2019) Chemical and pharmacological characterization of triptans. Bulletin of Medical Sciences 92:1, pages 53-60.
Crossref
Crossref
. (2018) The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache: The Journal of Head and Face Pain.
Crossref
Crossref
Uwe Reuter. (2018) A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine. Headache: The Journal of Head and Face Pain 58, pages 48-59.
Crossref
Crossref
Simona Guerzoni, Lanfranco Pellesi, Carlo Baraldi, Michela Maria Cainazzo, Andrea Negro, Paolo Martelletti & Luigi Alberto Pini. (2017) Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy. Frontiers in Neurology 8.
Crossref
Crossref
Balázs Marics, Barna Peitl, Kitti Pázmándi, Attila Bácsi, József Németh, Orsolya Oszlács, Gábor Jancsó & Mária Dux. (2017) Diet-Induced Obesity Enhances TRPV1-Mediated Neurovascular Reactions in the Dura Mater. Headache: The Journal of Head and Face Pain 57:3, pages 441-454.
Crossref
Crossref
Mirko Muzzi, Daniela Buonvicino, Francesco De Cesaris & Alberto Chiarugi. (2017) Acute and chronic triptan exposure neither alters rodent cerebral blood flow nor worsens ischemic brain injury. Neuroscience 340, pages 1-7.
Crossref
Crossref